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Synechia is the most frequent complication after sinus surgery and has been reported in up to 36% 
of cases. Several types of materials have been used to reduce the incidence of synechia, including 
Mitomycin C (MMC).
Objective: This prospective study aimed to assess the effectiveness of topical MMC in the preven-
tion of synechia after sinus surgery in humans.
Methods: At the end of surgery, MMC solution (1.0 mg/ml) was topically applied randomly to 
one of the middle meatuses (MMC group) of 14 patients while saline solution was applied to the 
contralateral meatus (control group). The author remained blind to the medicated side. Synechiae 
were classified as partial or total.
Results: Three patients had middle meatus synechia in the MMC group (21.43%) versus nine (64.29%) 
in the control group (p = 0.054). In the MMC group, all three middle meatus synechia were partial, 
while in the control group there were four partial (28.57%) and five total (35.71%) cases of synechia 
(p = 0.025).
Conclusions: Mitomycin C was not effective in preventing middle meatus synechia, but reduced 
the probability of total synechia formation.
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INTRODUCTION
The treatment of choice for refractory chronic 
rhinosinusitis is functional endoscopic sinus surgery 
(FESS), one of the most frequently performed pro-
cedures in the ENT practice. Despite its efficacy and 
safety, 7.6% to 38% of the patients experience relapsing 
symptoms and undergo revision surgery1,2. The causes 
of treatment failure include disturbed mucociliary clear-
ance, immunodeficiency, sensitivity to acetylsalicylic 
acid, and anatomic obstruction. The most frequent 
events related to the latter cause are synechia and 
ostium stenosis (27% in maxillary sinuses and 25% in 
frontal sinuses)3,4.
Postoperative synechia is the most frequently re-
ported complication in the literature, found in between 
11% and 36% of the cases. Revision surgery is required 
in 1% to 2% of the cases5-8. When only revision surgery 
is considered, the incidence rate ascends to 56%4. A 
review on 182 FESS patients revealed that the only find-
ings related to little clinical improvement were fibrosis 
in medial antrostomies and in the ethmoidal region3.
A number of different materials has been tried 
to reduce the rate of complications, among which are 
Merocel®, FloSeal™, Sepragel® and hyaluronic acid9. 
Mitomycin C (MMC) has also been studied as a means 
to prevent postoperative fibrosis.
MMC is an antibiotic-antineoplastic agent first iso-
lated from Streptomyces caespitosus in 195810. It inhibits 
the synthesis of DNA through a bifunctional alkylation 
that leads to the crossing of double helical strands not 
allowing neoplastic cells to proliferate. Higher dosages 
of MMC also inhibit the synthesis of RNA and proteins, 
and it has been used for many years now in oncology 
care. It inhibits scarring when used topically11.
The antiproliferative effect MMC has on human 
fibroblasts is the reason why it can modulate scarring 
and prevent excessive fibrosis formation. It has anti-
proliferative properties at 0.04mg/ml and, in higher 
dosages, offers cytocidal effects9,10.
One single topical application of MMC for 5 
minutes offers antiproliferative effects for up to 36 
hours9. When briefly applied to the human mucosa 
it reduces the replication of fibroblasts and increases 
their apoptosis10.
MMC was first used topically in 1963 as adjuvant 
therapy for pterygium11, reducing relapse rates from 
89% to 2.3%12. In glaucoma surgery it has proven ef-
fective in preventing stenosis of the trabeculectomy 
drainage fistula13. Additionally, it has improved the 
outcomes of dacriocistorhinostomy14,15.
MMC has been used more recently in ENT pro-
cedures such as laryngotracheal stenosis repairs16, to 
maintain patency in myringotomy17,18, and its use in 
sinus surgery has been successfully studied19-22.
Ingrams et al.19, in a trial with rabbits, looked 
into patency, antrostomy areas, and ciliary function of 
the mucosa treated with MMC dosages of 0.04 mg/mL, 
0.4 mg/mL and 1 mg/mL. The authors verified that 0.4 
mg/mL and 1 mg/mL of MMC maintained patency and 
antrostomy areas with a statistically significant differ-
ence against controls. Additionally, ciliary appearance 
and function returned to normal within two weeks 
and and the mucosal surface re-epithelialized nor-
mally. Rahal et al.20, using 1 mg/mL of MMC in rabbits, 
concluded the drug maintained antrostomy patency in 
areas significantly greater than saline solution without 
complications. However, studies in human beings with 
0.4 mg/mL and 0.5 mg/mL of MMC failed to replicate 
the outcomes seen in experimental trials23,24.
This paper aimed to assess the effectiveness of 
mitomycin C in humans to prevent synechia after func-
tional endoscopic sinus surgery in humans.
METHOD
This study was approved by the Research Eth-
ics Committee and granted permit nº 0191/04. The 
sample consisted of 15 patients (eight males and seven 
females) aged between 20 and 67 years (mean age of 
42.79 years) with chronic rhinosinusitis and referred 
to surgical treatmentsof Otorhinolaryngology. Patients 
were asked to sign an informed consent term. Inclu-
sion criteria: diagnosis of chronic rhinosinusitis as 
defined by the Consensus of the Brazilian Association 
of Otorhinolaryngology; age between 18 and 70 years; 
capacity to understand and sign the informed consent 
term; indication to undergo functional endoscopic sinus 
surgery. Exclusion criteria: pregnancy; primary cilia 
dyskinesia; cystic fibrosis; immunodeficiency; presence 
of nose or sinus tumor. One patient was excluded due 
to inadequate postoperative follow-up. The extent of 
disease was determined based on paranasal sinus CT 
scans and scored in accordance with the Lund-Mackay 
staging system.
All patients were operated under general anesthe-
sia by the author from May to October of 2006. Seventy-
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seven separate procedures were carried out. Three 
patients (21.43%) had allergic rhinitis, one (7.14%) had 
asthma, and one (7.14%) had systemic hypertension. 
Two patients (21.43%) had been previously operated for 
chronic rhinosinusitis. One had an antrostomy with bi-
lateral ethmoidectomy and a polypectomy respectively. 
The other had undergone two antrostomy procedures 
with ethmoidectomy.
In the beginning of the procedure the nasal 
cavities were filled with a 4x1 cm cotton swab soaked 
in 0.75% ropivacain with 1/100,000 UI epinephrine. 
Septal deviations hampering the access to ostiomeatal 
complexes were corrected at the start of the procedure. 
The extent and location of the disease determine which 
cavities would be approached.
Endoscopic surgery was done using 4-mm Karl 
Storz® 0°, 30° and 45° rigid scopes. The procedure was 
started with the placement of one surgical grade 2 x 1 
cotton swab soaked in 1/1.000 UI epinephrine in each 
middle meatus. Then the middle concha insertion was 
injected with 0.75% ropivacain and 1/100,000 UI epi-
nephrine solution.
The Messerklinger approach was used to treat 
the involved paranasal sinuses. Antrostomy proce-
dures were done in the posteroanterior orientation in 
a non-circular fashion with a diameter always greater 
than 3 mm as defined by Stammberger. At the end of 
the procedure a surgical grade 2 x 1 cotton swab with 
1 mL of MMC (1.0 mg/ml) was placed on one of the 
middle meatuses for 5 minutes. Another cotton swab 
soaked in 1 mL of saline solution was placed in the 
contralateral control middle meatus for 5 minutes. The 
cotton swabs were put in place by another team mem-
ber based on a randomization protocol produced on 
an Excel spreadsheet to blind the author. The cotton 
swabs were then removed and the middle meatuses 
packed with 10 x 2 rayon soaked in topical bacitracin 
until the next morning. All patients were given anti-
staphylococcus antibiotics after surgery for seven days 
and were advised to wash their noses with 20 mL of 
saline solution six times a day.
Postoperative visits were done one and two 
weeks, and one, three, six, and 12 months after sur-
gery. Patients were seen by the author, who remained 
blinded as to the group they belonged. The parameter 
assessed was presence of synechia in the middle me-
atus. Patients were inquired about pre and postopera-
tive symptoms and endoscopically examined by the 
author using 4-mm Karl Storz® 0°, 30° and 45° scopes. 
Synechia was characterized as adhesion between mu-
cosas and were categorizes as partial when the middle 
meatus was not completely obstructed and complete 
when they occluded them completely. Meatuses were 
deemed open only when no synechia was found.
Statistical analysis was done considering the 
scores assigned in the one-year postoperative visits, 
once they portrayed reality at the end of the study. The 
incidence rates of synechia in the middle meatuses in 
the groups were compared. The following statistical 
tests were used: λ2, sign test, Fisher’s exact test, Wil-
coxon signed-rank test, and z test.
RESULTS
Seventy-seven different procedures were per-
formed, namely: 30 antrostomies, 30 ethmoidectomies, 
eight sphenoidotomies, five frontal sinusotomies and 
four septoplasties. The mean Lund-Mackay score was 
14.50. The left side mean score was 7.36 and the right 
side mean score was 7.14. In the sides administered 
MMC the mean score was 7.14 while controls had a 
mean score of 7.36. This difference was not statistically 
significant (sign test, p = 0.50).
Variables gender, previous surgery, presence of 
polyps before surgery, and allergic rhinitis did not alter 
the results (Table 1), and neither did MMC administra-
tion (Fisher’s exact test, p = 0.18) (Table 2). The type 
of procedure performed did not alter the incidence rate 
of synechia (Table 3).
Variable Patients (n) Synechia (n) No synechia (n) p
Male 7 5 9
0.44
Female 7 7 7
Previous surgery 3 2 4 0.67
Polyps 4 2 6 0.40
Allergic rhinitis 3 3 3 1.00
Table 1. Incidence rates of middle meatus synechia and patient 
characteristics.
Table 2. Incidence rates of synechia based on side of middle 
meatus.
Side MMC
Synechia
p
Control Total
Right 3 3 6
Left 0 6 6
Total 3 9 12 0.18
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Graph 1. Incidence rates of middle meatus synechiae for each group.
Graph 2. Incidence rates of middle meatus synechia types for each 
group.
When synechia cases are considered separately, 
according to our classification the MMC group had 
three cases (21.43%) of partial synechia and no cases 
of complete synechia, while the control group had four 
cases (28.57%) of partial and five patients (35.71%) 
with complete synechia. This difference was statistically 
significant (λ2 test, p = 0.025) (Graph 2). Four patients 
had relapsing symptoms of rhinosinusitis in the control 
side. All had complete synechia, as opposed to the 
synechia-free side treated with MMC. None of the pa-
tients had to be re-operated, once symptoms subsided 
with clinical treatment.MMC was administered into nine (64.29%) right 
and five left (35.73%) middle meatuses. A total of 12 
cases of synechia (42.86%) were identified in ten of 
the 14 patients (z test, p = 0.57). Eight patients had 
synechia unilaterally and two bilaterally. In the eight 
cases of unilateral synechia, one patient had synechia 
in the side treated with MMC and seven had it in the 
control side as (z test, p = 0.07) (Table 4).
Table 3. Incidence rates of synechia based on performed 
procedure.
Procedure Synechia No synechia Total p
Antrostomy 12 16 28 0.57
Ethmoidectomy 12 16 28 0.57
Sphenoidotomy 3 5 8 0.73
Frontal sinusotomy 1 4 5 0.38
Septoplasty 1 3 4 0.62
Total 29 44 73
Table 4. Location of synechiae in 14 patients.
Side of synechia
Site of synechia Patients (n) MMC Control p
Unilateral 8 1 7 0.07
Bilateral 2
None 4
Total 14
One year after surgery, eleven (78.57%) middle 
meatuses treated with MMC and five (35.71%) in the 
saline solution group were free of synechia. Three 
middle meatuses in the MMC group (21.43%) and nine 
in the control group (64.29%) had synechia (Graph 1). 
There was no statistically significant difference between 
the groups (Fisher’s exact test, p = 0.054).
All patients claimed they improved one year after 
surgery. Additionally, none of them reported adverse 
effects or required re-operation during the study. Four 
patients had polyps after surgery, two in the side treated 
with MMC and two in the side given saline solution. 
They had had polyps prior to surgery. One patient 
complained of recurring headaches before surgery and 
still had this symptom throughout the study, although 
he claimed to have improved from rhinorrhea and na-
sal obstruction. This patient specifically had had two 
procedures before the study and had polyps after sur-
gery. Two patients had persistent thick nasal secretion 
in the control side which only improved after systemic 
administration of antibiotics. Two complications were 
observed: periorbital emphysema two weeks after 
surgery in one patient on the MMC-treated sideient.
DISCUSSION
One of the main precautions taken during FESS 
is avoiding intracranial and orbital complications that 
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may have severe irreversible consequences. These can 
be mitigated with thorough knowledge of the local 
anatomy, surgical experience, and proper preopera-
tive planning, so that our attention can be turned to 
trying to reduce postoperative complications such as 
synechia and stenosis.
According to the literature, synechia is the most 
frequent complication in functional endoscopic sinus 
surgery. It usually occurs between the middle concha 
and the lateral nasal wall25. The main cause of synechia 
is the non-preservation of the mucosa, allowing open 
areas to get in touch with and adhere to each other. 
Another less common cause is the presence of a pneu-
matized middle concha making it easier for the mucosa 
to touch the lateral nasal wall26.
The most effective measures to prevent the for-
mation of synechia are preserving the mucosa during 
surgery and carrying out careful postoperative care, 
dressing the surgical wounds and offering outpatient 
care at the first sign of adhesion. In spite of these mea-
sures, some authors advocate the partial resection of the 
middle concha as a means to avoid complications27-29. 
Nonetheless, they still occur quite frequently.
We decided to study the effectiveness of topi-
cal MMC in reducing scarring and fibrosis formation 
in middle meatuses and antrostomy sites because this 
drug has been used successfully with no adverse effects 
for 40 years in pterygium and glaucoma procedures. 
Another factor that led to the choice of MMC was the 
fact that it has been used with equal success in other 
areas of ENT care.
In FESS, Ingrams et al.19 and Rahal et al.20 have 
shown that 0.4 mg/mL and 1 mg/mL MMC can prevent 
fibrosis in experimental models. In an attempt to dem-
onstrate the same principle in humans, Chung et al.23 
and Anand et al.24 carried out randomized controlled 
trials using MMC at 0.4 mg/mL and 0.5 mg/mL respec-
tively, but no statistically significant differences were 
found when MMC was compared to saline solution. 
Nonetheless, as there was a tendency toward better 
results in patients treated with topical MMC, both au-
thors suggested that higher dosages and other drug 
presentations should be tested.
Therefore, this study looked into the use of topi-
cal 1 mg/mL MMC administered in one single dose dur-
ing surgery. Two complications occurred in our study: 
one case of periorbital subcutaneous emphysema 14 
days after surgery on the side in which MMC had been 
administered with dehiscence of the lamina papyracea 
in the middle meatus not visualized during surgery; and 
an asymptomatic perforation of 0.8 cm in the posterior 
septum along its larger diameter in a patient submitted 
to septoplasty and sinus surgery.
The emphysema was probably caused by the 
surgical procedure, even though the dehiscence of the 
lamina papyracea was not seen during surgery, and 
not by the use of MMC. The patient recovered fully in 
one week. The perforated septum may have occurred 
because the perichondrium was not preserved during 
the septoplasty procedure.
The chosen method allowed the consideration 
of differences between sides exclusively due to MMC, 
once each patient served as their own control. Besides, 
there was no statistical difference in the procedures 
done on each side of the nose, between the mean 
Lund-Mackay scores, and patient characteristics. MMC 
administration was randomized and postoperative as-
sessments were done by an examiner blinded for the 
side of MMC delivery.
The four patients with recurring symptoms had 
complete synechiae in their control meatuses and no 
synechia in their meatuses treated with MMC. This find-
ing suggests that this type of synechia may have been a 
determining factor for synechia occurrence. Thus, syn-
echiae were categorized as partial or complete. Given 
the efficacy of MMC in preventing the appearance of 
complete synechia, we may suggest that the drug led 
to a reduction on the recurrence of symptoms.
The rate of synechia in this study was 42.86% de-
spite the slightly lower rates reported by other authors, 
which ranged between 11% and 36%. This was probably 
due to the fact that mucosal adhesions of any kind, 
including filiform tissue structures, were categorized 
as synechia in this study. However, the comparisons 
were made between enrolled subjects, and not between 
them and cases reported in the literature. Although 
there was no statistically significant difference between 
the groups, there was a clear tendency toward better 
results in the group treated with MMC.
When the complete synechia cases alone are 
considered, incidence rates dropped to 0% in the MMC 
group and 17.86% in the control group, to thus reflect 
the rates found in the literature.
At first, the increase on the MMC dosage to 1 
mg/mL was not enough to prevent synechia formation, 
as reported by Chung et al.23 and Anand et al.24 for 
78(5) - inglês.indb   48 17/10/2012   15:04:02
49
Brazilian Journal of otorhinolaryngology 78 (5) SeptemBer/octoBer 2012
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
the 0.4 mg/mL and 0.5 mg/mL dosages respectively. 
On the other hand, unlike what both authors saw, we 
have proven that such increase in dosage is enough to 
prevent the occurrence of complete synechiae, one of 
the main symptom causing factors. Dosage and form 
of administration were not changed for that purpose.
The one-year follow-up period sat somewhere 
in the middle when compared to those used by Chung 
et al.23 and Anand et al.24 of four and 15 months re-
spectively. The period of one year seemed to be ap-
propriate, as most changes occurred within six months 
of follow-up.
We are aware that longer follow-up may reveal 
late complications and changes in outcome such as 
worsening of the meatuses treated with MMC. Given 
the significant time difference in the drug administra-
tion schedule of previous studies in relation to ours, 
future studies with intermediate dosages may be able 
to demonstrate the efficacy of the drug with higher 
safety levels.
The tendency toward better results with MMC 
despite the lack of statistical significance may be related 
to the small number of individuals enrolled in this study, 
vis-à-vis Chung et al.23 and Anand et al.24. Thus, given 
the high incidence rate of synechiae reported in the 
literature, an increase on the number of enrolled indi-
viduals may change the results reported in this study.
CONCLUSION
Mitomycin C was not effective in preventing post-
operative synechiae in patients submitted to functional 
endoscopic sinus surgery.
Mitomycin C was effective in preventing postop-
erative total synechiae in patients submitted to func-
tional endoscopic sinus surgery.
Studies with larger populations, higher dosages, 
and longer time of exposure are required.
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